CTOs on the Move


 
Suvoda’s sole focus is to offer the industry’s leading SaaS solution for randomization and trial supply management. Suvoda’s Interactive Response Technology (IRT/IWRS) combines the flexibility of a custom solution with the speed of a configurable platform, offering 4-week deployment, reimagined reporting, and easy integration.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.suvoda.com
  • 181 Washington Street Suite 100
    Conshohocken, PA USA 19428
  • Phone: 855.788.6321

Executives

Name Title Contact Details
Scot LeVan
Vice President of Global Information Technology Profile

Funding

Suvoda raised $40M on 12/05/2019

Similar Companies

Summit Counseling Solutions

Summit Counseling Solutions is a mental health care provider that offers adolescent day treatment and intensive outpatient services.

Gorbec Pharmaceuticals Services

Gorbec Pharmaceuticals Services is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FOCUS Pharmaceuticals

FOCUS Pharmaceuticals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hemagen Diagnostics

Hemagen Diagnostics is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.